Investigation into Potential Securities Fraud at Curanex Pharmaceuticals

Written by Emily J. Thompson, Senior Investment Analyst

Source: Newsfilter

Updated: 44 minutes ago

0mins

CURX-0.91%

Should l Buy CURX?

Source: Newsfilter

Securities Fraud Investigation: Wolf Haldenstein Adler Freeman & Herz LLP has announced an investigation into potential securities fraud involving Curanex Pharmaceuticals and its executives, aimed at protecting shareholder interests and pursuing possible legal claims.
IPO Details: Curanex conducted its Initial Public Offering on August 26, 2025, selling 3.75 million shares at $4.00 each, raising $15 million, indicating initial success in capital markets despite subsequent challenges.
Stock Price Volatility: Following the IPO, Curanex's stock peaked at $9.16 per share on September 16, 2025, but plummeted to $1.51 by the close on September 17 due to extreme volatility, with a trading volume of 26 million shares, highlighting market instability.
Law Firm Expertise: Wolf Haldenstein has extensive experience in securities class actions and derivative litigation, having been repeatedly appointed by courts to major roles in complex securities multi-district and consolidated litigation, underscoring its expertise and influence in such cases.

Trade with 70% Backtested Accuracy

Stop guessing "Should I Buy CURX?" and start using high-conviction signals backed by rigorous historical data.

Analyst Views on CURX

About CURX

Curanex Pharmaceuticals Inc is a developmental stage pharmaceutical company. The Company is engaged in discovering, developing, and commercializing botanical drugs to treat patients suffering from inflammatory diseases and to develop therapies that offer potential benefits to patients with unmet clinical needs in various fields, such as autoimmune diseases, metabolic diseases and viral infections. Its lead candidate, Phyto-N, is a botanical extract from a single plant with anti-inflammatory properties that act via multiple targets and mechanisms. Its drug development pipelines encompass six various therapeutic areas: ulcerative colitis, atopic dermatitis, COVID-19, diabetes, NAFLD, and gout. Phyto-N is being developed as an orally administered alternative for patients with moderate to severe ulcerative colitis, aiming to address limitations of current treatments. The Company's two botanical drugs include Veregen (sinecatechins) and Fulyzaq/Mytesi (crofelemer).

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

Curanex Pharmaceuticals Under Investigation for Potential Securities Fraud

31 minutes agoPRnewswire

Securities Fraud Investigation: Wolf Haldenstein Adler Freeman & Herz LLP is investigating potential securities fraud and other unlawful business practices involving Curanex Pharmaceuticals Inc., which may significantly impact shareholder rights and necessitate investor vigilance regarding legal repercussions.
IPO Details: Curanex conducted its Initial Public Offering on August 26, 2025, selling 3.75 million shares at $4.00 each, raising a total of $15 million, indicating initial market confidence in its botanical drug development efforts.
Severe Stock Volatility: Following the IPO, Curanex's stock peaked at $9.16 per share on September 16, 2025, but was halted the next day due to extreme volatility, plummeting to $1.51 per share on a trading volume of 26 million shares, highlighting significant market instability.
Legal Expertise: Wolf Haldenstein has extensive experience in prosecuting securities class actions and derivative litigation, having been repeatedly appointed by courts to major roles in complex securities multi-district and consolidated litigation, underscoring its capability in protecting investor interests.